Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Bögemann

Showing results (21-30 of 100) with videos related to

Pageof 10
Sort By:
Expert Review of Anticancer Therapy|December 27, 2005
The endothelin axis in urologic tumors: mechanisms of tumor biology and therapeutic implicationsEdwin Herrmann, Martin Bögemann, Stefan Bierer, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 17, 2020
Radioligand therapy using [<sup>177</sup>Lu]Lu-PSMA-617 in mCRPC: a pre-VISION single-center analysisRobert Seifert, Katharina Kessel, Katrin Schlack, et al.
Aktuelle Urologie|March 19, 2021
[Apalutamide in patients with high-risk M0CRPC: data from the pivotal SPARTAN study and initial experience from a compassionate use program]Eva Hellmis, Christian Schwentner, Philipp Mandel, et al.
Aktuelle Urologie|February 23, 2021
[Apalutamide in patients with high-risk M0CRPC: data from the pivotal SPARTAN study and initial experience from a compassionate use program]Eva Hellmis, Christian Schwentner, Philipp Mandel, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 16, 2018
Advantage of <sup>18</sup>F-PSMA-1007 over <sup>68</sup>Ga-PSMA-11 PET imaging for differentiation of local recurrence vs. urinary tracer excretionKambiz Rahbar, Matthias Weckesser, Hojjat Ahmadzadehfar, et al.
Irish Journal of Medical Science|March 22, 2023
Role of apalutamide in the treatment landscape for patients with advanced prostate cancer: an expert opinion statement of European clinical practiceMartin Bögemann, Gaetano Facchini, Thomas Bauernhofer, et al.
Clinical Genitourinary Cancer|August 17, 2024
Immune-Related Adverse Events Can Predict Progression-Free and Overall Survival In Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint InhibitorsMatteo Silberg, Laura-Maria Krabbe, Martin Bögemann, et al.
BJU International|January 24, 2018
Performance comparison of two androgen receptor splice variant 7 (AR-V7) detection methodsChristof Bernemann, Julie Steinestel, Verena Humberg, et al.
Clinical Nuclear Medicine|April 19, 2016
Radioligand Therapy With 177Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate CancerKambiz Rahbar, Axel Bode, Matthias Weckesser, et al.
World Journal of Nuclear Medicine|December 23, 2020
Do fasting or high caloric drinks affect the physiological uptake of fluorine-18 prostate-specific membrane antigen-1007 in liver and bowel?Kambiz Rahbar, Ali Afshar-Oromieh, Robert Seifert, et al.
Pageof 10

Showing results (21-30 of 100) with videos related to

Sort By:
Pageof 10
Expert Review of Anticancer Therapy|December 27, 2005
The endothelin axis in urologic tumors: mechanisms of tumor biology and therapeutic implicationsEdwin Herrmann, Martin Bögemann, Stefan Bierer, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 17, 2020
Radioligand therapy using [<sup>177</sup>Lu]Lu-PSMA-617 in mCRPC: a pre-VISION single-center analysisRobert Seifert, Katharina Kessel, Katrin Schlack, et al.
Aktuelle Urologie|March 19, 2021
[Apalutamide in patients with high-risk M0CRPC: data from the pivotal SPARTAN study and initial experience from a compassionate use program]Eva Hellmis, Christian Schwentner, Philipp Mandel, et al.
Aktuelle Urologie|February 23, 2021
[Apalutamide in patients with high-risk M0CRPC: data from the pivotal SPARTAN study and initial experience from a compassionate use program]Eva Hellmis, Christian Schwentner, Philipp Mandel, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 16, 2018
Advantage of <sup>18</sup>F-PSMA-1007 over <sup>68</sup>Ga-PSMA-11 PET imaging for differentiation of local recurrence vs. urinary tracer excretionKambiz Rahbar, Matthias Weckesser, Hojjat Ahmadzadehfar, et al.
Irish Journal of Medical Science|March 22, 2023
Role of apalutamide in the treatment landscape for patients with advanced prostate cancer: an expert opinion statement of European clinical practiceMartin Bögemann, Gaetano Facchini, Thomas Bauernhofer, et al.
Clinical Genitourinary Cancer|August 17, 2024
Immune-Related Adverse Events Can Predict Progression-Free and Overall Survival In Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint InhibitorsMatteo Silberg, Laura-Maria Krabbe, Martin Bögemann, et al.
BJU International|January 24, 2018
Performance comparison of two androgen receptor splice variant 7 (AR-V7) detection methodsChristof Bernemann, Julie Steinestel, Verena Humberg, et al.
Clinical Nuclear Medicine|April 19, 2016
Radioligand Therapy With 177Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate CancerKambiz Rahbar, Axel Bode, Matthias Weckesser, et al.
World Journal of Nuclear Medicine|December 23, 2020
Do fasting or high caloric drinks affect the physiological uptake of fluorine-18 prostate-specific membrane antigen-1007 in liver and bowel?Kambiz Rahbar, Ali Afshar-Oromieh, Robert Seifert, et al.
Pageof 10